Caplyta

Active Ingredient(s): Lumateperone
FDA Approved: * December 20, 2019
Pharm Company: * INTRA-CELLULAR THERAPIES INC
Category: Antipsychotic

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Caplyta Overview

Lumateperone (INN; brand name Caplyta kp-LY-t, developmental codes ITI-007 and ITI-722) is a butyrophenone atypical antipsychotic developed by Intra-Cellular Therapies, licensed from Bristol-Myers Squibb, for the treatment of schizophrenia,[2] and currently in development for bipolar depression and other neurological indications.[3] The most common side effects include sleepiness and dry mouth.[4] Contents 1 Medical uses 1.1 Schizophrenia 2...

Read more Caplyta Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Lumateperone

Recent Caplyta Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Caplyta: (1 result)

Sorted by National Drug Code

• 72060-142 Caplyta 42 mg Oral Capsule by Intra-cellular Therapies, Inc

Other drugs which contain Lumateperone or a similar ingredient: (1 result)

• LUMATEPERONE